{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T07:19:29Z","timestamp":1790493569175,"version":"4.1.0"},"reference-count":101,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,12,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The non-Hodgkin lymphomas (NHLs) occurring in children and adolescents and young adults (AYA) are characterized by various age-related differences in tumor biology and survival. Children generally present with high-grade lymphomas, such as Burkitt lymphoma, diffuse large B-cell lymphoma, lymphoblastic lymphoma, and anaplastic large cell lymphoma, whereas low-grade histologic subtypes, such as follicular lymphoma, occur more frequently with increasing age. Treatment outcome for children with NHL is generally superior to that observed in adults. Factors contributing to this discrepancy include psychosocial factors, patient factors, and differences in tumor biology and therapy. These factors will be reviewed, with particular attention to the biological features of diffuse large B-cell lymphoma and anaplastic large cell lymphoma and corresponding therapeutic challenges. Novel targeting agents have been developed, which have been shown to be active in some patients. There is clearly a need for treatment protocols with eligibility criteria that cover the full span of the pediatric and AYA age range and that incorporate detailed molecular characterization of the tumors.<\/jats:p>","DOI":"10.1182\/asheducation-2016.1.589","type":"journal-article","created":{"date-parts":[[2016,12,2]],"date-time":"2016-12-02T11:05:27Z","timestamp":1480676727000},"page":"589-597","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":75,"title":["Non-Hodgkin lymphoma across the pediatric and adolescent and young adult age spectrum"],"prefix":"10.1182","volume":"2016","author":[{"given":"John T.","family":"Sandlund","sequence":"first","affiliation":[{"name":"Department of Oncology, St. Jude Children\u2019s Research Hospital, Memphis, TN;"},{"name":"Department of Pediatrics, University of Tennessee College of Medicine, Memphis TN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike G.","family":"Martin","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Tennessee College of Medicine, Memphis, TN; and"},{"name":"The West Cancer Center, Memphis TN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"19","key":"2019111707281735800_B1","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1056\/NEJM199605093341906","article-title":"Non-Hodgkin\u2019s lymphoma in childhood","volume":"334","author":"Sandlund","year":"1996","journal-title":"N Engl J Med"},{"issue":"27","key":"2019111707281735800_B2","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1200\/JCO.2014.59.5827","article-title":"Non-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges Ahead","volume":"33","author":"Minard-Colin","year":"2015","journal-title":"J Clin Oncol"},{"issue":"22","key":"2019111707281735800_B3","doi-asserted-by":"crossref","first-page":"5803","DOI":"10.1182\/blood-2010-12-283093","article-title":"Malignant hematologic diseases in adolescents and young adults","volume":"117","author":"Wood","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2019111707281735800_B4","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1053\/j.seminoncol.2009.07.009","article-title":"Lymphoma in adolescents and young adults","volume":"36","author":"Jaglowski","year":"2009","journal-title":"Semin Oncol"},{"key":"2019111707281735800_B5","doi-asserted-by":"crossref","DOI":"10.1182\/asheducation-2007.1.297","article-title":"Should Adolescents with NHL Be Treated as Old Children or Young Adults?","author":"Sandlund","year":"2007"},{"issue":"4","key":"2019111707281735800_B6","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3322\/canjclin.57.4.242","article-title":"Young adult oncology: the patients and their survival challenges","volume":"57","author":"Bleyer","year":"2007","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2019111707281735800_B7","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2141.2005.05735.x","article-title":"The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence","volume":"131","author":"Burkhardt","year":"2005","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111707281735800_B8","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s11899-015-0277-y","article-title":"Non-Hodgkin Lymphoma in Children","volume":"10","author":"Sandlund","year":"2015","journal-title":"Curr Hematol Malig Rep"},{"issue":"6","key":"2019111707281735800_B9","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.clml.2014.12.006","article-title":"Influence of insurance and marital status on outcomes of adolescents and young adults with acute lymphoblastic leukemia","volume":"15","author":"Fintel","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"14","key":"2019111707281735800_B10","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma. The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"2019111707281735800_B11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1289\/ehp.94102s11111","article-title":"Pharmacokinetics in the child","volume":"102","author":"Crom","year":"1994","journal-title":"Environ Health Perspect"},{"issue":"3","key":"2019111707281735800_B12","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1182\/blood-2003-06-2094","article-title":"Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL","volume":"104","author":"Pfreundschuh","year":"2004","journal-title":"Blood"},{"issue":"3","key":"2019111707281735800_B13","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood-2003-06-2095","article-title":"Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL","volume":"104","author":"Pfreundschuh","year":"2004","journal-title":"Blood"},{"issue":"9226","key":"2019111707281735800_B14","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0140-6736(00)02503-4","article-title":"Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia","volume":"356","author":"Relling","year":"2000","journal-title":"Lancet"},{"key":"2019111707281735800_B15","article-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008","journal-title":"IARC Press"},{"issue":"9","key":"2019111707281735800_B16","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1182\/blood-2014-04-571091","article-title":"ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes","volume":"124","author":"Parrilla Castellar","year":"2014","journal-title":"Blood"},{"issue":"25","key":"2019111707281735800_B17","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111707281735800_B18","first-page":"847","article-title":"Are pediatric and adult diffuse large B-cell lymphoma the same disease?","volume":"46","author":"Perkins","year":"2006","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"2019111707281735800_B19","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.3109\/10428194.2014.883075","article-title":"Moving beyond rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone for diffuse large B-cell lymphoma","volume":"55","author":"Roschewski","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2019111707281735800_B20","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/bjh.14011","article-title":"Molecular genetics of childhood, adolescent and young adult non-Hodgkin lymphoma","volume":"173","author":"Miles","year":"2016","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111707281735800_B21","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/pbc.21619","article-title":"Pediatric diffuse large B-cell lymphoma demonstrates a high proliferation index, frequent c-Myc protein expression, and a high incidence of germinal center subtype: Report of the French-American-British (FAB) international study group","volume":"51","author":"Miles","year":"2008","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"2019111707281735800_B22","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"issue":"1","key":"2019111707281735800_B23","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","article-title":"Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity","volume":"125","author":"Sehn","year":"2015","journal-title":"Blood"},{"issue":"6","key":"2019111707281735800_B24","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1365-2141.2009.07762.x","article-title":"BCL2 expression in de novo diffuse large B-cell lymphoma partly reflects normal differences in age distribution","volume":"146","author":"Thunberg","year":"2009","journal-title":"Br J Haematol"},{"issue":"10","key":"2019111707281735800_B25","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2005-10-4213","article-title":"Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) Multicenter Trial","volume":"107","author":"Oschlies","year":"2006","journal-title":"Blood"},{"issue":"1","key":"2019111707281735800_B26","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1182\/blood-2011-01-330795","article-title":"Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults","volume":"118","author":"Salaverria","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2019111707281735800_B27","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3324\/haematol.2009.013177","article-title":"Pediatric follicular lymphoma--a clinico-pathological study of a population-based series of patients treated within the Non-Hodgkin\u2019s Lymphoma--Berlin-Frankfurt-Munster (NHL-BFM) multicenter trials","volume":"95","author":"Oschlies","year":"2010","journal-title":"Haematologica"},{"issue":"8","key":"2019111707281735800_B28","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood-2010-09-297879","article-title":"Double-hit B-cell lymphomas","volume":"117","author":"Aukema","year":"2011","journal-title":"Blood"},{"issue":"7","key":"2019111707281735800_B29","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1182\/blood-2006-07-036665","article-title":"Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents","volume":"109","author":"Cairo","year":"2007","journal-title":"Blood"},{"issue":"11","key":"2019111707281735800_B30","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood.V97.11.3370","article-title":"The Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Oncologie P\u00e9diatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia","volume":"97","author":"Patte","year":"2001","journal-title":"Blood"},{"issue":"7","key":"2019111707281735800_B31","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1182\/blood-2006-07-036673","article-title":"Results of the randomized international FAB\/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients","volume":"109","author":"Patte","year":"2007","journal-title":"Blood"},{"issue":"3","key":"2019111707281735800_B32","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2004-03-0973","article-title":"The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95","volume":"105","author":"Woessmann","year":"2005","journal-title":"Blood"},{"issue":"5","key":"2019111707281735800_B33","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/leu.2012.255","article-title":"Rituximab and FAB\/LMB 96 chemotherapy in children with Stage III\/IV B-cell non-Hodgkin lymphoma: a Children\u2019s Oncology Group report","volume":"27","author":"Goldman","year":"2013","journal-title":"Leukemia"},{"issue":"3","key":"2019111707281735800_B34","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/bjh.13040","article-title":"Rituximab with chemotherapy in children and adolescents with central nervous system and\/or bone marrow-positive Burkitt lymphoma\/leukaemia: a Children\u2019s Oncology Group Report","volume":"167","author":"Goldman","year":"2014","journal-title":"Br J Haematol"},{"key":"2019111707281735800_B35","doi-asserted-by":"crossref","first-page":"Abstract 10507","DOI":"10.1200\/JCO.2016.34.15_suppl.10507","article-title":"Results of the randomized intergroup trial Inter-B-NHL Ritux 2010 for children and adolescents iwth high-risk B-cell non-Hodgkin lymphoma (B-NHL) and mature acute leukemia (B-AL): Evaluation of rituximab (R) efficacy in addition to standard LMB chemotherapy (CT) regimen [abstract]","volume":"34","author":"Minard-Colin","year":"2016","journal-title":"J Clin Oncol"},{"issue":"19","key":"2019111707281735800_B36","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1200\/JCO.2009.26.6791","article-title":"Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin\u2019s lymphoma and Burkitt leukemia","volume":"28","author":"Meinhardt","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111707281735800_B37","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1182\/blood-2012-04-422709","article-title":"Outcome and pathologic classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB\/LMB96 mature B-NHL therapy","volume":"121","author":"Gerrard","year":"2013","journal-title":"Blood"},{"issue":"15","key":"2019111707281735800_B38","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1214561","article-title":"Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma","volume":"368","author":"Dunleavy","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111707281735800_B39","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111707281735800_B40","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"issue":"2","key":"2019111707281735800_B41","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol"},{"issue":"6","key":"2019111707281735800_B42","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(13)70122-0","article-title":"Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial","volume":"14","author":"Delarue","year":"2013","journal-title":"Lancet Oncol"},{"issue":"18","key":"2019111707281735800_B43","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMoa1301077","article-title":"Autologous transplantation as consolidation for aggressive non-Hodgkin\u2019s lymphoma","volume":"369","author":"Stiff","year":"2013","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111707281735800_B44","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S1470-2045(11)70069-9","article-title":"Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial","volume":"12","author":"Peyrade","year":"2011","journal-title":"Lancet Oncol"},{"issue":"15","key":"2019111707281735800_B45","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1182\/blood-2014-05-578963","article-title":"Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis","volume":"124","author":"Petrich","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2019111707281735800_B46","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1056\/NEJMc1305983","article-title":"Therapy in primary mediastinal B-cell lymphoma","volume":"369","author":"Cashen","year":"2013","journal-title":"N Engl J Med"},{"issue":"18","key":"2019111707281735800_B47","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1002\/cncr.25278","article-title":"Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma","volume":"116","author":"Abramson","year":"2010","journal-title":"Cancer"},{"issue":"6","key":"2019111707281735800_B48","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/bjc.2014.405","article-title":"A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma","volume":"111","author":"Cheah","year":"2014","journal-title":"Br J Cancer"},{"issue":"5","key":"2019111707281735800_B49","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1182\/blood-2013-10-535021","article-title":"The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomas","volume":"124","author":"Murawski","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2019111707281735800_B50","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/bjh.13273","article-title":"Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group","volume":"169","author":"Purroy","year":"2015","journal-title":"Br J Haematol"},{"issue":"16","key":"2019111707281735800_B51","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1200\/JCO.2007.13.1391","article-title":"Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers","volume":"26","author":"Wilson","year":"2008","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111707281735800_B52","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.21776","article-title":"Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"issue":"5","key":"2019111707281735800_B53","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1002\/cncr.22089","article-title":"Secondary chromosomal abnormalities predict outcome in pediatric and adult high-stage Burkitt lymphoma","volume":"107","author":"Onciu","year":"2006","journal-title":"Cancer"},{"issue":"23","key":"2019111707281735800_B54","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa055759","article-title":"Molecular diagnosis of Burkitt\u2019s lymphoma","volume":"354","author":"Dave","year":"2006","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111707281735800_B55","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1200\/JCO.1993.11.6.1024","article-title":"Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin\u2019s lymphoma: a report of CCG-551 from the Childrens Cancer Group","volume":"11","author":"Anderson","year":"1993","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111707281735800_B56","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1200\/JCO.1999.17.8.2461","article-title":"Hyper-CVAD program in Burkitt\u2019s-type adult acute lymphoblastic leukemia","volume":"17","author":"Thomas","year":"1999","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111707281735800_B57","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1200\/JCO.1996.14.3.925","article-title":"Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen","volume":"14","author":"Magrath","year":"1996","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111707281735800_B58","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1182\/blood.V85.3.664.bloodjournal853664","article-title":"Small noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols","volume":"85","author":"Soussain","year":"1995","journal-title":"Blood"},{"issue":"20","key":"2019111707281735800_B59","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa1308392","article-title":"Low-intensity therapy in adults with Burkitt\u2019s lymphoma","volume":"369","author":"Dunleavy","year":"2013","journal-title":"N Engl J Med"},{"key":"2019111707281735800_B60","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3109\/10428199309149117","article-title":"Ki-1-anaplastic large cell lymphoma: is it a discrete entity?","volume":"10","author":"Stein","year":"1993","journal-title":"Leuk Lymphoma"},{"issue":"5151","key":"2019111707281735800_B61","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1126\/science.8122112","article-title":"Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin\u2019s lymphoma","volume":"263","author":"Morris","year":"1994","journal-title":"Science"},{"issue":"25","key":"2019111707281735800_B62","doi-asserted-by":"crossref","first-page":"6756","DOI":"10.1182\/blood-2010-05-231548","article-title":"Peripheral T-cell lymphoma","volume":"117","author":"Foss","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2019111707281735800_B63","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/PAS.0000000000000500","article-title":"Morphologic Features of ALK-negative Anaplastic Large Cell Lymphomas With DUSP22 Rearrangements","volume":"40","author":"King","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"2019111707281735800_B64","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1182\/blood.V93.11.3913","article-title":"Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma","volume":"93","author":"Gascoyne","year":"1999","journal-title":"Blood"},{"issue":"3","key":"2019111707281735800_B65","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1200\/JCO.2005.11.075","article-title":"Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial","volume":"23","author":"Laver","year":"2005","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111707281735800_B66","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1200\/JCO.2008.18.1487","article-title":"Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group","volume":"27","author":"Brugi\u00e8res","year":"2009","journal-title":"J Clin Oncol"},{"issue":"30","key":"2019111707281735800_B67","doi-asserted-by":"crossref","first-page":"5056","DOI":"10.1200\/JCO.2008.20.1764","article-title":"Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: a report from the French Society of Pediatric Oncology","volume":"27","author":"Brugi\u00e8res","year":"2009","journal-title":"J Clin Oncol"},{"issue":"25","key":"2019111707281735800_B68","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.2010.28.5999","article-title":"Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial","volume":"28","author":"Le Deley","year":"2010","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111707281735800_B69","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1002\/pbc.25187","article-title":"Advanced stage anaplastic large cell lymphoma in children and adolescents: results of ANHL0131, a randomized phase III trial of APO versus a modified regimen with vinblastine: a report from the children\u2019s oncology group","volume":"61","author":"Alexander","year":"2014","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"2019111707281735800_B70","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/leu.2012.205","article-title":"Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis","volume":"27","author":"Mussolin","year":"2013","journal-title":"Leukemia"},{"issue":"19","key":"2019111707281735800_B71","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N Engl J Med"},{"issue":"18","key":"2019111707281735800_B72","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111707281735800_B73","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1470-2045(13)70095-0","article-title":"Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children\u2019s Oncology Group phase 1 consortium study","volume":"14","author":"Moss\u00e9","year":"2013","journal-title":"Lancet Oncol"},{"issue":"1","key":"2019111707281735800_B74","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.3324\/haematol.2015.131151","article-title":"Phase II trial of dose-adjusted EPOCH in untreated systemic anaplastic large cell lymphoma","volume":"101","author":"Dunleavy","year":"2016","journal-title":"Haematologica"},{"issue":"4","key":"2019111707281735800_B75","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1046\/j.1365-2141.2000.02098.x","article-title":"Autologous stem cell transplantation for anaplastic large-cell lymphomas: results of a prospective trial","volume":"109","author":"Deconinck","year":"2000","journal-title":"Br J Haematol"},{"issue":"25","key":"2019111707281735800_B76","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"d\u2019Amore","year":"2012","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111707281735800_B77","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00277-013-1716-2","article-title":"Autologous stem cell transplantation as consolidation therapy for patients with peripheral T cell lymphoma in first remission: long-term outcome and risk factors analysis","volume":"92","author":"Czyz","year":"2013","journal-title":"Ann Hematol"},{"issue":"5","key":"2019111707281735800_B78","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.bbmt.2015.01.013","article-title":"Comparison of survival in patients with T cell lymphoma after autologous and allogeneic stem cell transplantation as a frontline strategy or in relapsed disease","volume":"21","author":"Beitinjaneh","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2019111707281735800_B79","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1093\/annonc\/mdg459","article-title":"High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience","volume":"14","author":"Rodr\u00edguez","year":"2003","journal-title":"Ann Oncol"},{"issue":"6","key":"2019111707281735800_B80","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00277-007-0254-1","article-title":"High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival","volume":"86","author":"Kim","year":"2007","journal-title":"Ann Hematol"},{"issue":"1","key":"2019111707281735800_B81","first-page":"CD004024","article-title":"High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive non-Hodgkin lymphoma (NHL) in adults","author":"Greb","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"2019111707281735800_B82","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/PPO.0b013e31826aef4a","article-title":"Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma","volume":"18","author":"Foyil","year":"2012","journal-title":"Cancer J"},{"issue":"8","key":"2019111707281735800_B83","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMc1013224","article-title":"Crizotinib in anaplastic large-cell lymphoma","volume":"364","author":"Gambacorti-Passerini","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111707281735800_B84","doi-asserted-by":"crossref","first-page":"djt378","DOI":"10.1093\/jnci\/djt378","article-title":"Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients","volume":"106","author":"Gambacorti Passerini","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"16","key":"2019111707281735800_B85","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1182\/blood-2012-12-474148","article-title":"Incidence and prognostic relevance of genetic variations in T-cell lymphoblastic lymphoma in childhood and adolescence","volume":"121","author":"Bonn","year":"2013","journal-title":"Blood"},{"issue":"2","key":"2019111707281735800_B86","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/pbc.20550","article-title":"Gene expression profiling reveals intrinsic differences between T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma","volume":"47","author":"Raetz","year":"2006","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"2019111707281735800_B87","first-page":"416","article-title":"Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report","volume":"95","author":"Reiter","year":"2000","journal-title":"Blood"},{"issue":"3","key":"2019111707281735800_B88","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1200\/JCO.2005.02.2707","article-title":"Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma","volume":"24","author":"Burkhardt","year":"2006","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111707281735800_B89","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1038\/leu.2008.400","article-title":"Effective treatment of advanced-stage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: results of St Jude NHL13 study","volume":"23","author":"Sandlund","year":"2009","journal-title":"Leukemia"},{"issue":"6","key":"2019111707281735800_B90","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/bjh.12460","article-title":"Disseminated lymphoblastic lymphoma in children and adolescents: results of the COG A5971 trial: a report from the Children\u2019s Oncology Group","volume":"162","author":"Termuhlen","year":"2013","journal-title":"Br J Haematol"},{"issue":"7","key":"2019111707281735800_B91","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1002\/pbc.24149","article-title":"Outcome of newly diagnosed children and adolescents with localized lymphoblastic lymphoma treated on Children\u2019s Oncology Group trial A5971: a report from the Children\u2019s Oncology Group","volume":"59","author":"Termuhlen","year":"2012","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"2019111707281735800_B92","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1182\/blood-2010-06-292615","article-title":"Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children\u2019s Oncology Group (POG 9404)","volume":"118","author":"Asselin","year":"2011","journal-title":"Blood"},{"issue":"21","key":"2019111707281735800_B93","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1200\/JCO.2008.21.1318","article-title":"Minimal disseminated disease in childhood T-cell lymphoblastic lymphoma: a report from the children\u2019s oncology group","volume":"27","author":"Coustan-Smith","year":"2009","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111707281735800_B94","doi-asserted-by":"crossref","first-page":"4379","DOI":"10.1182\/blood-2002-01-0110","article-title":"Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia","volume":"99","author":"Hoelzer","year":"2002","journal-title":"Blood"},{"issue":"6","key":"2019111707281735800_B95","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1182\/blood-2003-12-4428","article-title":"Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"issue":"3","key":"2019111707281735800_B96","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/annonc\/mdl426","article-title":"Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic stem-cell transplantation results in favorable outcomes","volume":"18","author":"Song","year":"2007","journal-title":"Ann Oncol"},{"issue":"6","key":"2019111707281735800_B97","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.V99.6.1959","article-title":"Clinicopathologic analysis of follicular lymphoma occurring in children","volume":"99","author":"Lorsbach","year":"2002","journal-title":"Blood"},{"issue":"12","key":"2019111707281735800_B98","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1182\/blood-2012-05-429514","article-title":"Pediatric-type nodal follicular lymphoma: an indolent clonal proliferation in children and adults with high proliferation index and no BCL2 rearrangement","volume":"120","author":"Louissaint","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2019111707281735800_B99","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/bjh.13359","article-title":"Uncommon non-Hodgkin lymphomas of childhood: pathological diagnosis, clinical features and treatment approaches","volume":"169","author":"Sandlund","year":"2015","journal-title":"Br J Haematol"},{"issue":"11","key":"2019111707281735800_B100","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1007\/s00277-013-1785-2","article-title":"Children and adolescents with follicular lymphoma have an excellent prognosis with either limited chemotherapy or with a \u201cWatch and wait\u201d strategy after complete resection","volume":"92","author":"Attarbaschi","year":"2013","journal-title":"Ann Hematol"},{"issue":"7","key":"2019111707281735800_B101","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/leu.2014.91","article-title":"How we manage follicular lymphoma","volume":"28","author":"Hiddemann","year":"2014","journal-title":"Leukemia"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2016\/1\/589\/1251708\/hem088335.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2016\/1\/589\/1251708\/hem088335.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T07:28:45Z","timestamp":1573975725000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2016\/1\/589\/21139\/NonHodgkin-lymphoma-across-the-pediatric-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,2]]},"references-count":101,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12,2]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2016.1.589","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,2]]}}}